RAF1 and cancer: Medolution Limited Corporation protected a series of deuterated derivatives of sorafenib and regorafenib as multitarget kinase inhibitors for the treatment of VEGFR, PDGFR and/or RAF mediated cancer diseases (Zhang, 2012).